Cellectis to raise EUR 20.5 million in private placement
Cellectis S.A. (Euronext:ALCLS) plans to raise EUR 20.5 million ($28.3 million) through the sale of 4 million shares at EUR 5.13 in a private placement to U.S. institutional investors. The price is a 3% premium to Cellectis' close of EUR 4.99 on Monday, before the company proposed the offering. OrbiMed Advisors will lead the offering. venBio; Ridgeback Capital; Aquilo Capital; and Merlin Nexus will also participate.
Cellectis is developing a pipeline of cancer immunotherapies with its gene editing technologies. Next year, the company plans to start Phase I testing of lead candidate UCART19 for leukemia. The product, which comprises chimeric antigen receptor (CAR)-modified, CD19-targeted allogeneic T cells, is partnered with Servier (Neuilly-sur-Seine, France). ...